ClinicalTrials.gg
Not yet recruitingNCT07823725TD-LungUpdated Sep 21, 2026

TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling

An interventional study of True Dose® Capillary Self-Sampling System in Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), sponsored by Karolinska Institutet. Not yet recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 111 studies in Carcinoma, Non-Small-Cell Lung with a site in Sweden — 24 open to participants now, 42 under way, 26 of them phase 3. Carcinoma, Non-Small-Cell Lung · Sweden.

Planned enrollment
96th of 106
40 · median 376
Started
2026
with 5 others
No phase
6 of 111
3 open now
Primary completion
2028-10
later than 27 of 41 live
Registered
111th of 111
by date

Among the 111 studies in Carcinoma, Non-Small-Cell Lung with a site in Sweden, this one is the 96th largest by planned enrollment of the 106 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 with no phase, reaches primary completion later than 27 of the 41 other live ones, and was the 111th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

24 of the 111 studies in Carcinoma, Non-Small-Cell Lung with a site in Sweden are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Carcinoma, Non-Small-Cell Lung with a site in Sweden, or all of them as a file.
02

Study summary

This study will evaluate whether people with non-small cell lung cancer (NSCLC) can collect small blood samples themselves using a finger-prick sampling kit. Participants will be receiving standard treatment with docetaxel, paclitaxel, alectinib, or lorlatinib.

The blood samples will be used to measure the amount of cancer medicine in the blood. Most samples will be collected by participants at home and returned to a laboratory for analysis. The study will assess how easy the sampling method is to use, whether the collected samples are suitable for laboratory analysis, and how patients and healthcare professionals experience this way of collecting blood samples.

The study will also explore whether measured drug levels are related to side effects, dose changes, treatment delays, or other clinical outcomes. The drug-level results collected in this study will be used for research purposes and will not be used to change participants' cancer treatment.

About 80 participants will take part in the study and will be followed for approximately 3 months.

The microsampling device is CE-marked and used within its approved use exclusively for research and feasibility evaluation. Study results do not influence ongoing clinical treatment decisions.

This study is being conducted as part of Project-COMFORT, a European multi-country initiative aiming to evaluate the feasibility and implementation of PCmS across various populations and healthcare systems.

Read the detailed description

This prospective, non-interventional feasibility and implementation study evaluates decentralized therapeutic drug monitoring (TDM) using capillary self-sampling in adults with non-small cell lung cancer (NSCLC) receiving standard-of-care treatment with docetaxel, paclitaxel, alectinib, or lorlatinib. The study focuses on the feasibility, usability, and implementation of patient-centric microsampling in routine oncology care.

Participants will be trained to collect a small capillary whole-blood sample using a finger prick. Samples will be collected mainly at home and returned by mail for laboratory analysis. Sampling schedules are adapted to the treatment received. For participants receiving taxanes, capillary samples are collected at defined time points after infusion. For participants receiving ALK inhibitors, samples are collected at home in relation to the scheduled oral dose.

The primary focus of the study is whether participants can successfully perform capillary self-sampling and whether the returned samples are suitable for laboratory analysis. Participant experience, usability, need for assistance, and practical aspects of integrating home-based sampling into oncology care will also be evaluated. Qualitative interviews or focus groups with patients and healthcare professionals will explore barriers and facilitators to implementation and the potential impact of decentralized sampling on clinical workflows.

Drug concentrations will be measured for research purposes. Exploratory analyses will examine associations between drug exposure and clinical measures such as treatment-related toxicity, dose modifications or delays, hospital visits, and clinical response when available. In participants with both capillary and venous samples, the relationship between concentrations measured using the two sampling methods may also be evaluated.

Participants will continue to receive their prescribed cancer treatment according to standard clinical practice. The study does not introduce an investigational medicinal product, randomize participants, or require treatment changes based on study measurements. Drug concentration results obtained through capillary self-sampling will not be used to guide treatment decisions during the study.

03

Conditions studied

  • Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)

Keywords

  • Therapeutic drug monitoring
  • Patient-centric microsampling
  • Capillary self-sampling
  • Precision dosing
  • Docetaxel
  • Alectinib
  • Lorlatinib
  • ALK inhibitors
  • Taxanes
  • Paclitaxel
  • Feasiblity reserach
  • Implementation research
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥18 years. or cytologically confirmed non-small cell lung cancer (NSCLC). Receiving ongoing standard-of-care treatment with docetaxel, paclitaxel, alectinib, or lorlatinib.

Able to understand Swedish or English and provide written . Willing and able to comply with study-required procedures, including blood sample collection.

Able to perform capillary self-sampling at home, with or without support from a caregiver or healthcare professional.

Access to a stable home or remote environment suitable for sample collection and, where applicable, home nurse visits.

Able to participate in the required sample collection and shipping procedures, independently or with support from a family member or caregiver.

Exclusion criteria

Exclusion Criteria:

Concurrent participation in another interventional study that may affect pharmacokinetics.

Severe coagulopathy or another to capillary blood sampling. Known to a previously used adhesion system used for sample collection.

Any condition that, in the investigator's judgment, would make study participation unsafe or infeasible, including skin infection or another skin condition at the intended sample collection site.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Taxane Cohort

    Participants with non-small cell lung cancer receiving standard-of-care treatment with docetaxel or paclitaxel will use the True Dose® capillary self-sampling system for collection of blood samples for therapeutic drug monitoring research. Participants will perform capillary sampling at predefined time points following taxane administration. Study drug concentration results will not be used to guide treatment decisions.

    Device: True Dose® Capillary Self-Sampling System

  • Experimental
    ALK Inhibitor Cohort

    Participants with non-small cell lung cancer receiving standard-of-care treatment with alectinib or lorlatinib will use the True Dose® capillary self-sampling system for collection of blood samples for therapeutic drug monitoring research. Capillary samples will be collected at home in relation to the participant's regular oral treatment. Study drug concentration results will not be used to guide treatment decisions.

    Device: True Dose® Capillary Self-Sampling System

Interventions

  • DeviceTrue Dose® Capillary Self-Sampling System

    The True Dose® capillary self-sampling system is a patient-centric microsampling system that enables collection of approximately 50 µL of capillary whole blood using a finger prick. Participants are trained to perform capillary blood collection, primarily at home, and samples are returned by mail for laboratory analysis of drug concentrations. The study evaluates the feasibility, usability, and sample suitability of decentralized capillary self-sampling for therapeutic drug monitoring. Results from study-specific drug concentration measurements will be used for research purposes and will not be used to guide participants' cancer treatment.

This study also gives Alectinib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Successful Decentralized Capillary Self-Sampling With Reportable Drug Concentration

    Proportion of participants who successfully complete at least one scheduled home capillary self-sampling procedure resulting in a laboratory-approved sample and a reportable drug concentration. Success is defined as completion of all of the following: (1) participant performs the capillary self-collection within the predefined sampling window; (2) the sample is received by the laboratory; (3) the sample meets predefined laboratory suitability criteria, including sufficient sample volume and acceptable sample integrity; and (4) the relevant drug concentration can be successfully quantified using the validated analytical method. The outcome will be reported as the number and percentage of participants meeting all criteria.

    Time frame: From first scheduled home sampling until completion of the sampling period, approximately 1 month.

Secondary outcomes

  1. Usability and Acceptability of Capillary Self-Sampling

    Participant-rated ease of performing capillary self-sampling, assessed using the study-specific patient questionnaire. Participants rate the statement "It was easy to take the blood sample myself" on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicate greater perceived ease of use. Results will be reported as the distribution of responses and/or median and interquartile range. Participant acceptability of decentralized capillary self-sampling, assessed using the study-specific patient questionnaire on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicate greater acceptability. The predefined acceptability item will assess willingness to use home capillary self-sampling as part of future cancer care.

    Time frame: Through study completion, approximately 3 months

  2. Need for Assistance With Capillary Self-Sampling

    Proportion of participants who require assistance or report difficulty when using the capillary self-sampling system. This outcome will assess whether the training materials and instructions are sufficient to support participants in performing the sampling procedure.

    Time frame: Through study completion, approximately 3 months

  3. Laboratory Sample Suitability

    Number and proportion of returned capillary blood samples meeting all predefined laboratory suitability criteria for drug concentration analysis. A sample will be classified as suitable when sufficient sample volume is available, sample integrity is acceptable, and the sample can proceed to quantitative analysis according to the predefined laboratory procedures. The denominator will be all capillary samples received by the laboratory.

    Time frame: Through study completion, approximately 3 months

  4. Barriers and Facilitators to Implementation of Capillary Self-Sampling

    Barriers and facilitators to implementation of patient-centric microsampling will be explored through semi-structured focus groups and/or interviews with patients and healthcare professionals. The evaluation will address uptake and adherence, trust, usability and acceptability, training needs, effects on clinical workflow and communication, and patient autonomy. Interviews will be audio-recorded, transcribed verbatim, and analyzed using qualitative content analysis.

    Time frame: Through study completion, approximately 3 months

Other outcomes

  1. Capillary Blood Concentration of Docetaxel

    Docetaxel concentration measured in capillary blood at predefined sampling time points using the validated quantitative analytical method. Concentrations will be reported in ng/mL.

    Time frame: At predefined pharmacokinetic sampling time points during docetaxel treatment, through study completion, approximately 3 months.

  2. Capillary Blood Concentration of Paclitaxel

    Paclitaxel concentration measured in capillary blood at predefined sampling time points using the validated quantitative analytical method. Concentrations will be reported in ng/mL.

    Time frame: At predefined pharmacokinetic sampling time points during paclitaxel treatment, through study completion, approximately 3 months.

  3. Capillary Blood Trough Concentration (Cmin) of Alectinib

    lectinib trough concentration (Cmin) measured in capillary blood at the predefined steady-state sampling time point. Concentrations will be reported in ng/mL.

    Time frame: At predefined steady-state sampling during alectinib treatment, through study completion, approximately 3 months.

  4. Capillary Blood Trough Concentration (Cmin) of Lorlatinib

    Lorlatinib trough concentration (Cmin) measured in capillary blood at the predefined steady-state sampling time point. Concentrations will be reported in ng/mL.

    Time frame: At predefined steady-state sampling during lorlatinib treatment, through study completion, approximately 3 months.

07

Study locations

2 sites
  • Institution of Oncology-Pathology
    Stockholm, 17166, Sweden
  • Karolinska Univeristy Hospital, Theme Cancer, Lung Cancer Department
    Stockholm, 17176, Sweden
08

References and documents

Publications

  • Groenland SL, Geel DR, Janssen JM, de Vries N, Rosing H, Beijnen JH, Burgers JA, Smit EF, Huitema ADR, Steeghs N. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients. Clin Pharmacol Ther. 2021 Feb;109(2):394-402. doi: 10.1002/cpt.1989. Epub 2020 Aug 19. PubMed 32686074 ↗
  • Maass KF, Barfield MD, Ito M, James CA, Kavetska O, Kozinn M, Kumar P, Lepak M, Leuthold LA, Li W, Mikhailov D, Patel S, Perez NL, Jackson Rudd D, Vakkalagadda B, Williams TM, Zha J, Zhang X, Anderson MD. Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: Promise to reality. Clin Transl Sci. 2022 Dec;15(12):2785-2795. doi: 10.1111/cts.13411. Epub 2022 Oct 8. PubMed 36129129 ↗
  • Komninos N, De Chiara S, Checa A, Wiklander O, Rydberg P, Hedayati E. Development and evaluation of a novel capillary blood collection method for decentralized therapeutic drug monitoring using the True Dose kit. Sci Rep. 2025 Sep 29;15(1):33331. doi: 10.1038/s41598-025-20951-5. PubMed 41023074 ↗
  • Crafoord MT, Hedayati E, Johnsson A. Capillary Blood Self-Sampling for Therapeutic Drug Monitoring: A Mixed-Methods Usability Study of the True Dose(R) Kit. Biomed Res Int. 2025 Jul 9;2025:9973081. doi: 10.1155/bmri/9973081. eCollection 2025. PubMed 40678388 ↗
  • Mc Laughlin AM, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland SL, Huitema ADR, Steeghs N, Muller L, Fuxius S, Illerhaus G, Joerger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers (Basel). 2021 Dec 14;13(24):6281. doi: 10.3390/cancers13246281. PubMed 34944899 ↗
  • Kicken MP, Deenen MJ, van der Wekken AJ, van den Borne BEEM, van den Heuvel MM, Ter Heine R. Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine. Clin Pharmacokinet. 2025 Apr;64(4):511-531. doi: 10.1007/s40262-025-01492-6. Epub 2025 Mar 5. PubMed 40045151 ↗
  • Beumer JH. Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther. 2013 Mar;93(3):228-30. doi: 10.1038/clpt.2012.243. No abstract available. PubMed 23419487 ↗
  • Hertz DL, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, Gandara D, Stahl M, Monk BJ, Jaehde U, Beumer JH. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer. 2024 May;202:114024. doi: 10.1016/j.ejca.2024.114024. Epub 2024 Mar 19. PubMed 38513383 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 344 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 98. This study's planned 24 months is below that.

Counting every sponsor, half of 360 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2026
First posted
Sep 16, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2029
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07823725
Collaborators
Project-COMFORT, Stockholm School of Economics Institute for Research (SIR), ALK Positive Sverige, Sweden, True Dose AB, Vinnova, Karolinska University Hospital
Responsible party
Elham Hedayati (MD, PhD, Karolinska Institutet) — Principal investigator
First posted
Sep 16, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Sep 21, 2026

Study contacts

Elin Backman Stålnacke, Speciliased Nurse in Oncology
Contact
elin.backman-stalnacke@regionstockholm.se
+46 8 123 711 85
Elham Hedayati, MD PhD
Contact
elham.hedayati@ki.se
+46 709261035
Simon Ekman, Professor, MD, PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion